Argenx SE (ARGX):企業の財務・戦略的SWOT分析

◆英語タイトル:Argenx SE (ARGX) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH140762FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オランダ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥66,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥99,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Argenx SE (Argenx) is a human antibodies developer. The company offers autoimmunity and oncology products. Its wholly owned product candidates include ARGX-113, ARGX-110, ARGX-117 and ARGX-111. Argenx partnered product candidates are ARGX-109, ARGX-112, ARGX-115 AND ARGX-116. The company offers treatment for T-cell lymphoma, nasopharyngeal cancer, chronic myelogenous leukemia and MET amplified cancer among others. It offers product such as Efgartigimod, Cusatuzumab and candidates to myasthenia gravis immune thromocytopeniapemphigus valgaris chronic auto immune diseases, T cell lymphoma, acute myeloid leukemia and blood cancer. Argenx products are used for the treatment of inflammatory and autoimmune diseases. The company develops antibodies using its proprietary technology platforms such as NHance, simple antibody technology, and others. It operates offices in the Netherlands and Belgium. Argenx is headquartered in Breda, the Netherlands.

Argenx SE Key Recent Developments

Mar 04,2021: argenx reports full year 2020 financial results and provides fourth quarter business update
Mar 04,2021: argenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Business Update argenx today reported financial results for the full year 2020 and provided a fourth quarter business update. Read
Feb 04,2021: argenx announces full exercise of underwriters option to purchase additional ADSs
Jan 11,2021: argenx to Present at 39th Annual J.P. Morgan Healthcare Conference argenx today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 8:20 a.m. ET. Re
Jan 07,2021: L2 : Business Expansions : argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China argenx SE and Zai Lab Limited today announced an exclusive license agreement for the development and commercialization of efgartigimod in Greater Read

This comprehensive SWOT profile of Argenx SE provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Argenx SE including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Argenx SE – Key Information
Argenx SE – Overview
Argenx SE – Key Employees
Argenx SE – Key Employee Biographies
Argenx SE – Key Operational Heads
Argenx SE – Major Products and Services
Argenx SE – History
Argenx SE – Company Statement
Argenx SE – Locations And Subsidiaries
Argenx SE
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Argenx SE – Business Description
Argenx SE – Corporate Strategy
Argenx SE – SWOT Analysis
SWOT Analysis – Overview
Argenx SE – Strengths
Argenx SE – Weaknesses
Argenx SE – Opportunities
Argenx SE – Threats
Argenx SE – Key Competitors

Section 3 – Company Financial Performance Charts

Argenx SE – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Argenx SE, Key Information
Argenx SE, Key Ratios
Argenx SE, Share Data
Argenx SE, Major Products and Services
Argenx SE, History
Argenx SE, Key Employees
Argenx SE, Key Employee Biographies
Argenx SE, Key Operational Heads
Argenx SE, Other Locations
Argenx SE, Subsidiaries
Argenx SE, Key Competitors
Argenx SE, SWOT Analysis
Argenx SE, Ratios based on current share price
Argenx SE, Annual Ratios
Argenx SE, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Argenx SE (ARGX):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Kerecis ehf:製薬・医療:M&Aディール及び事業提携情報
    Summary Kerecis ehf (Kerecis) is a medical device company that provides products that treats chronic wounds and damaged tissue. The company’s flagship product includes Kerecis Omega3 fish-skin acellular dermal matrix transplantation technology is intended for use in products to treat acute, chronic …
  • Ivoclar Vivadent AG:医療機器:M&Aディール及び事業提携情報
    Summary Ivoclar Vivadent AG (Ivoclar Vivadent) is an international dental products providing company. It manufactures material systems for high quality dental applications. The company’s products include impression materials, adhesives, temporary materials, restorative materials, all-ceramics, lutin …
  • CytRx Corp (CYTR):製薬・医療:M&Aディール及び事業提携情報
    Summary CytRx Corp (CytRx) is a clinical state is a biopharmaceutical company focusing on the research and development of novel treatments for cancer. The company’s oncology based product comprises of its lead drug product candidate, aldoxorubicin (formerly INNO-206). Aldoxorubicin is a pro-drug of …
  • ACWA Power Barka SAOG (APBS):企業の財務・戦略的SWOT分析
    ACWA Power Barka SAOG (APBS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Dentsu, Inc.:企業の戦略・SWOT・財務情報
    Dentsu, Inc. - Strategy, SWOT and Corporate Finance Report Summary Dentsu, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Beckman Coulter Inc:医療機器:M&Aディール及び事業提携情報
    Summary Beckman Coulter Inc (Beckman), is a subsidiary of Danaher Corp, is a manufacturer of biomedical testing instrument systems. It develops, manufactures and markets biomedical laboratory instruments, software and other things that simplify and automate complex biomedical tests. The company offe …
  • Angion Biomedica Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Angion Biomedica Corp (Angion) is a clinical-stage organ restoration biopharmaceutical company that discovers and develops novel treatments for the treatment of renal and chronic organ injury and disease. The company’s pipeline products include BB3, ANG-3070, ANG-3586, ANG-4201, TBD and ANG- …
  • BioCision LLC-製薬・医療分野:企業M&A・提携分析
    Summary BioCision LLC (BioCision) is a life science research and development company that develops products and solutions for process standardization. The company’s products include cell cryopreservation systems, ice-free cooling systems, tube and plate temperature management systems, cell thawing s …
  • Urstadt Biddle Properties Inc:企業の戦略・SWOT・財務分析
    Urstadt Biddle Properties Inc - Strategy, SWOT and Corporate Finance Report Summary Urstadt Biddle Properties Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Professional Insurance Corp Zambia PLC:企業の戦略・SWOT・財務分析
    Professional Insurance Corp Zambia PLC - Strategy, SWOT and Corporate Finance Report Summary Professional Insurance Corp Zambia PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • SSY Group Ltd (2005):企業の財務・戦略的SWOT分析
    Summary SSY Group Ltd (SSY), formerly Lijun International Pharmaceutical (Holding) Co Ltd is a pharmaceutical company that offers range of pharmaceutical products such as intravenous infusion solution. The company offers glass bottle infusion solutions, non-PVC soft bag infusions, and PP plastic bot …
  • Orthofix International N.V. (OFIX):医療機器:M&Aディール及び事業提携情報
    Summary Orthofix International NV (Orthofix) is a medical device company that designs, develops, manufactures and distributes medical devices related to spine and orthopedic. Its solutions include spinal implants; human cellular and tissue based products; non-invasive regenerative stimulation produc …
  • Ngai Hing Hong Co Ltd (1047):企業の財務・戦略的SWOT分析
    Ngai Hing Hong Co Ltd (1047) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • LG Life Science LTD (068870)-製薬・医療分野:企業M&A・提携分析
    Summary LG Life Science LTD (LGLS) is a global life science company that offers development, production and marketing of pharmaceutical products. The company provides pipeline of antibiotic, Factive and other drug candidates. Its products include vaccines, anti-infective, chemicals, veterinary medic …
  • Shields Bag And Printing Company:企業の戦略・SWOT・財務分析
    Shields Bag And Printing Company - Strategy, SWOT and Corporate Finance Report Summary Shields Bag And Printing Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • ACHEM Technology Corporation:企業の戦略・SWOT・財務情報
    ACHEM Technology Corporation - Strategy, SWOT and Corporate Finance Report Summary ACHEM Technology Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • CompuGroup Medical Deutschland AG (COP)-医療機器分野:企業M&A・提携分析
    Summary CompuGroup Medical Deutschland AG (CGM) is a provider of medical software products and healthcare services. The company's products comprise communication solutions, software assisted medicine, dentist information systems, ambulatory information systems, drug safety, patient marketing, and ot …
  • Forestar Group Inc:企業の戦略・SWOT・財務情報
    Forestar Group Inc - Strategy, SWOT and Corporate Finance Report Summary Forestar Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Famous Dave’s of America, Inc.:戦略・SWOT・企業財務分析
    Famous Dave's of America, Inc. - Strategy, SWOT and Corporate Finance Report Summary Famous Dave's of America, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Havas SA:企業の戦略・SWOT・財務分析
    Havas SA - Strategy, SWOT and Corporate Finance Report Summary Havas SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆